RE:Game theoryFrom the June 5th 2019 conference call re: bracelet collaboration.BTW both parties are splitting the costs evenly from different PR's that I have looked at.
The design of BRACELET-1 study is going to be the same as our successful IND 213 study in metastatic breast cancer patients with the addition of a treatment arm to include pelareorep. It's an open label, 45 patient, three arm study that captures efficacy data in real time that all three companies will have access to. This data includes biomarker and disease control rate through week-16 of each patient's treatment. Our goal is experience in order to move into a Phase 3 program in this indication. Now with that in mind we are working closely with our collaborators to determine the most realistic and rapid timeline possible and will provide an update on this after confirming with clinical investigators and trial sites.